Business
BioCryst develops and markets medicines for rare diseases.
BioCryst grew revenue, remained profitable, generated positive free cash flow at a 39.0% operating margin. High margins and free cash flow contrasted with a distress-range balance-sheet screen.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 94.1%OK
- Profitability — The company moved from a net loss of $88.881M to net income of $263.861MOK
- Cash flow — Free cash flow turned positive at $344.901M from an outflow of $53.144MOK
- Margins — Operating margin expanded 3954 bps to 38.98%OK
- Accounting — High margins and free cash flow contrasted with a distress-range balance-sheet screenWatch
- Insiders — 0 purchases and 11 salesWatch
Where the revenue comes from
Fiscal 2025, as BIOCRYST PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Product sales, net$623.2M
- ORLADEYO$601.8M
- License and other revenues$251.7M
- Other revenues$29.0M
- RAPIVAB$12.2M
Leadership changes
From BIOCRYST PHARMACEUTICALS INC's own filings, the day they're filed.
- Jon Stonehouse · Chief Executive Officer · departureeff. 2025-12-31
- Vincent J. Milano · departureeff. 2025-12-09
- Charlie Gayer · President · appointmenteff. 2025-08-01
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-29
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BIOCRYST PHARMACEUTICALS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.